Bille Andrea, Woo Kaitlin M, Ahmad Usman, Rizk Nabil P, Jones David R
Department of Thoracic Surgery, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
Department of Epidemiology and Biostatistics, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
Eur J Cardiothorac Surg. 2017 Apr 1;51(4):674-679. doi: 10.1093/ejcts/ezw400.
Early clinical stage (T1 and T2) non-small cell lung cancer (NSCLC) is commonly treated with anatomic lung resection and lymph node sampling or dissection. The aims of this study were to evaluate the incidence and the distribution of occult N2 disease according to tumour location and the short- and long-term outcomes.
We performed a retrospective review of patients with clinical stage I NSCLC who underwent anatomic lung resection and lymphadenectomy. Mediastinal lymphadenectomy (ML) was defined as resection of at least 2 mediastinal stations, always including station 7 lymph nodes. Patients who had a lobe-specific lymphadenectomy were excluded.
One thousand six hundred and sixty-seven consecutive patients met inclusion criteria and were included. Overall, 9% (146/1667) of the patients had occult pN2 disease. At multivariable analysis, adenocarcinoma histology and vascular invasion were independently associated with greater risk of occult pN2 disease. In left and right upper lobe tumours, station 7 nodes were involved in 5 and 13% of pN2 positive cases, respectively. Station 5 and station 2/4 nodes were involved in 29 and 18% of left and right lower lobe pN2 tumours, respectively. There was no postoperative mortality, and postoperative morbidity was 28%. The median overall survival was 77.4 months. N0 patients had a median overall survival of 83.7 months vs 48.0 months and 37.9 months in N1 and N2 populations, respectively ( P < 0.001).
Sixteen percent of pN2 patients had mediastinal lymph node metastasis beyond the lobe-specific lymphatic drainage. We recommend a complete lymphadenectomy be performed, even in clinical stage I NSCLC.
早期临床分期(T1和T2)非小细胞肺癌(NSCLC)通常采用肺解剖性切除及淋巴结采样或清扫术治疗。本研究旨在根据肿瘤位置评估隐匿性N2期疾病的发生率和分布情况以及短期和长期结局。
我们对接受肺解剖性切除及淋巴结清扫术的临床I期NSCLC患者进行了回顾性研究。纵隔淋巴结清扫术(ML)定义为至少切除2个纵隔淋巴结站,且始终包括第7组淋巴结。行叶特异性淋巴结清扫术的患者被排除。
1667例连续患者符合纳入标准并被纳入研究。总体而言,9%(146/1667)的患者存在隐匿性pN2期疾病。多变量分析显示,腺癌组织学类型和血管侵犯与隐匿性pN2期疾病风险增加独立相关。在左上叶和右上叶肿瘤中,第7组淋巴结在pN2阳性病例中受累比例分别为5%和13%。第5组淋巴结以及第2/4组淋巴结在左下叶和右下叶pN2肿瘤中受累比例分别为29%和18%。无术后死亡病例,术后并发症发生率为28%。中位总生存期为77.4个月。N0患者的中位总生存期为83.7个月,而N1和N2患者分别为48.0个月和37.9个月(P < 0.001)。
16%的pN2患者存在叶特异性淋巴引流以外的纵隔淋巴结转移。我们建议即使是临床I期NSCLC患者也应行完整的淋巴结清扫术。